---
document_datetime: 2024-09-12 11:26:36
document_pages: 9
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/veraseal-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: veraseal-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 5.9792836
conversion_datetime: 2025-12-27 17:35:38.702861
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## VeraSeal

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| N/0039               | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                     | 11/09/2024                          |                                             | PL                               |           |
| IB/0038              | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process | 28/08/2024                          | n/a                                         |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| IG/1776   | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                     | 24/07/2024   | n/a        |             |                                                                      |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|----------------------------------------------------------------------|
| IB/0035   | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                       | 14/06/2024   | n/a        |             |                                                                      |
| IG/1755   | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                     | 28/05/2024   | n/a        |             |                                                                      |
| IB/0034   | B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)                                                                                                                             | 08/05/2024   | n/a        |             |                                                                      |
| IG/1729   | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                     | 11/03/2024   | n/a        |             |                                                                      |
| II/0027   | Extension of indication to include treatment of children for VeraSeal, based on final results from study IG1405; this is a prospective, randomized, active-controlled, single-blind, parallel group clinical trial to evaluate the safety and efficacy of VeraSeal | 14/12/2023   | 25/01/2024 | SmPC and PL | Please refer to Scientific Discussion 'VeraSeal-H-C-004446- II-0027' |

<div style=\"page-break-after: always\"></div>

|                     | as an adjunct to haemostasis during surgery in paediatric subjects. As a consequence, sections 4.1, 4.2 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 7.0 of the RMP has also been submitted. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one   |            |     |                                   |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| PSUSA/10297 /202306 | Periodic Safety Update EU Single assessment - human fibrinogen / human thrombin                                                                                                                                                                                                                                                                                         | 11/01/2024 | n/a | PRAC Recommendation - maintenance |
| IG/1687             | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                                                                                                                          | 27/11/2023 | n/a |                                   |
| IG/1673             | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                                                                                                                          | 02/10/2023 | n/a |                                   |
| IA/0028             | B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier                                                                                                                                                                                                                              | 12/06/2023 | n/a |                                   |
| IB/0025/G           | This was an application for a group of variations. B.II.b.3.a - Change in the manufacturing process of                                                                                                                                                                                                                                                                  | 26/05/2023 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

|         | in the manufacturing process B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size   |            |            |                       | the finished   |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|----------------|
| IG/1602 | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes not affect the properties of the FP                                                                                                                                                                                                                                               | 13/03/2023 | n/a        |                       | do             |
|         | This was an application for a group of variations. B.II.f.1.b.z - Stability of FP - Extension of the shelf life of the finished product - Other variation B.II.f.1.z - Stability of FP - Change in the shelf-life or storage conditions of the finished product - Other variation                                                                                                                                                                                                         | 11/01/2023 | 25/01/2024 | SmPC, Annex II and PL | IB/0023/G      |
| IG/1578 | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                                                                                                                                                                                                                                            | 29/11/2022 | n/a        |                       |                |

<div style=\"page-break-after: always\"></div>

| IG/1563   | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                                                                                                                                                        | 05/10/2022   | n/a        |                                  |                         |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|-------------------------|
| R/0018    | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                               | 21/07/2022   | 19/09/2022 | SmPC, Annex II, Labelling and PL |                         |
| IG/1536   | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                                                                                                                                                        | 13/07/2022   | n/a        |                                  |                         |
| IB/0020   | B.V.a.1.b - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - First-time inclusion of a new PMF NOT affecting the properties of the FP                                                                                                                                                                       | 29/06/2022   | n/a        |                                  |                         |
| IG/1500/G | This was an application for a group of variations. B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier | 25/03/2022   | n/a        |                                  | of a medicinal product. |

<div style=\"page-break-after: always\"></div>

|                     | Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                                                                                                                                                        |            |            |               |                                   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|---------------|-----------------------------------|
| N/0017              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                               | 20/12/2021 | 19/09/2022 | PL            |                                   |
| IG/1402             | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP | 09/06/2021 | n/a        |               |                                   |
| N/0015              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                               | 06/04/2021 | 19/09/2022 | PL            |                                   |
| PSUSA/10297 /202006 | Periodic Safety Update EU Single assessment - human fibrinogen / human thrombin                                                                                                                                                                | 14/01/2021 | n/a        |               | PRAC Recommendation - maintenance |
| IG/1328             | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP | 07/01/2021 | n/a        |               |                                   |
| IG/1298             | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP | 08/10/2020 | n/a        |               |                                   |
| N/0011              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                               | 30/09/2020 | 18/11/2020 | Labelling and |                                   |

<div style=\"page-break-after: always\"></div>

|                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |            |            | PL                               |                                   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-----------------------------------|
| IG/1252             | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                                                                                                                                                                                                                                                                                                                                                           | 11/05/2020 | n/a        |                                  |                                   |
| PSUSA/10297 /201906 | Periodic Safety Update EU Single assessment - human fibrinogen / human thrombin                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 16/01/2020 | n/a        |                                  | PRAC Recommendation - maintenance |
| IG/1188             | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                                                                                                                                                                                                                                                                                                                                                           | 05/12/2019 | n/a        |                                  |                                   |
| II/0006/G           | This was an application for a group of variations. B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.e.6.a - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that affects the product information B.II.e.6.a - Change in any part of the (primary) packaging material not in contact with the finished | 14/11/2019 | 18/11/2020 | SmPC, Annex II, Labelling and PL |                                   |

<div style=\"page-break-after: always\"></div>

|                     | product information B.IV.1.a.3 - Change of a measuring or administration device - Addition or replacement of a device which is not an integrated part of the primary packaging - Spacer device for metered dose inhalers or other device which may have a significant impact on the delivery of the AS   |            |     |                                                                                                                                                                                                                                                                      |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/1161             | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                                                           | 08/10/2019 | n/a |                                                                                                                                                                                                                                                                      |
| IG/1048             | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                                                           | 07/03/2019 | n/a |                                                                                                                                                                                                                                                                      |
| PSUSA/10297 /201806 | Periodic Safety Update EU Single assessment - human fibrinogen / human thrombin                                                                                                                                                                                                                          | 17/01/2019 | n/a | PRAC Recommendation - maintenance                                                                                                                                                                                                                                    |
| PSUSA/10297 /201712 | Periodic Safety Update EU Single assessment - human fibrinogen / human thrombin                                                                                                                                                                                                                          | 12/07/2018 | n/a | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Evicel in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| IG/0937             | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) -                                                                                                                                                   | 16/05/2018 | n/a |                                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

|         | Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                                                                                                                                                        |            |     |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IG/0902 | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP | 12/02/2018 | n/a |